Key result
Circulating, imaging, and genetic biomarkers show promise for predicting early and late CTRCD.
Why the study?
Cardiotoxicity from breast cancer therapies is a serious complication, but the management of cancer therapy-related cardiac dysfunction lacks clinical evidence and is based on limited studies.
Do clinical biomarkers predict the early and late onset of cancer therapy-related cardiac dysfunction in women receiving breast cancer therapies?
Systematic Review
Do clinical biomarkers predict the early and late onset of cancer therapy-related cardiac dysfunction in women receiving breast cancer therapies?
Clinical biomarkers are crucial for developing alternative risk cardiac stratification plans to predict and manage therapy-induced cardiotoxicity in breast cancer patients.
May refine cardiotoxicity risk stratification in breast cancer patients; leaves open prospective validation before routine adoption.
Cardiotoxicity induced by breast cancer therapies is a potentially serious complication associated with the use of various breast cancer therapies. Prediction and better management of cardiotoxicity in patients receiving chemotherapy is of critical importance. However, the management of cancer therapy-related cardiac dysfunction (CTRCD) lacks clinical evidence and is based on limited clinical studies. AIM: To provide an overview of existing and potentially novel biomarkers that possess a promising predictive value for the early and late onset of CTRCD in the clinical setting. METHODS: A systematic review of published studies searching for promising biomarkers for the prediction of CTRCD in patients with breast cancer was undertaken according to PRISMA guidelines. A search strategy was performed using PubMed, Google Scholar, and Scopus for the period 2013-2023. All subjects were >18 years old, diagnosed with breast cancer, and received breast cancer therapies. RESULTS: The most promising biomarkers that can be used for the development of an alternative risk cardiac stratification plan for the prediction and/or early detection of CTRCD in patients with breast cancer were identified. CONCLUSIONS: We highlighted the new insights associated with the use of currently available biomarkers as a standard of care for the management of CTRCD and identified potentially novel clinical biomarkers that could be further investigated as promising predictors of CTRCD.
No takes yet. Share an insight, caveat, or question.
Alexandraki et al. (2023) conducted a systematic review in Breast Cancer (receiving systemic cardiotoxic therapy). Clinical Biomarkers (Troponins, Natriuretic Peptides, LVEF, Genetic variants) was evaluated on Prediction and/or early detection of cancer therapy-related cardiac dysfunction (CTRCD). Existing and potentially novel clinical biomarkers (including cardiac troponins, natriuretic peptides, imaging parameters, and genetic variants) show promise for predicting the early and late onset of cancer therapy-related cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: